UK Cannabis Research 2024 — Key Studies, Clinical Trials

UK Cannabis Research 2024 — Key Studies and Clinical Trials

The United Kingdom has emerged as a significant hub for cannabis research, particularly following the legalisation of medical cannabis in 2018. In 2024, the landscape of cannabis research in the UK continues to expand with groundbreaking studies, expanded clinical trials, and evolving regulatory frameworks. This comprehensive guide explores the latest developments in cannabis research UK and what they mean for patients, healthcare professionals, and the broader scientific community.

The Evolution of Cannabis Research in the UK

Cannabis research in the UK has undergone a remarkable transformation over the past five years. The rescheduling of cannabis-based medicinal products (CBMPs) as Schedule 2 controlled drugs in November 2018 marked a pivotal moment, enabling licensed medical professionals to prescribe cannabis for specific medical conditions. This shift has catalysed numerous clinical trials and observational studies.

As of 2024, the UK hosts several major research institutions conducting cannabis-related investigations, including Imperial College London, King’s College London, and the University of Oxford. These institutions have collectively contributed to a growing body of evidence supporting both the efficacy and safety profile of medical cannabis.

Key Clinical Trials in 2024

Several landmark clinical trials have progressed significantly throughout 2024, providing crucial data on cannabis efficacy for various conditions. The EPIC (Epidemiological Program on Investigational Cannabinoid Clinical Trials) study continues to track long-term outcomes for patients using medical cannabis, with preliminary data suggesting sustained therapeutic benefits for epilepsy, chronic pain, and multiple sclerosis-related spasticity.

The PIVOT trial, focused on intractable epilepsy in children, has produced encouraging results, with approximately 64% of participating paediatric patients experiencing a reduction in seizure frequency of 50% or greater. This represents significant progress in addressing treatment-resistant epilepsy, which affects roughly 30% of childhood epilepsy cases in the UK.

Additionally, the Real-world Evidence for Cannabinoid Treatment (REACT) study has expanded its participant base to over 5,000 patients, making it one of Europe’s largest observational studies examining cannabis use in routine clinical practice across NHS and private settings.

Medical Conditions Under Investigation

Current cannabis research in the UK examines numerous medical conditions. Epilepsy remains the condition with the strongest evidence base, particularly for rare, treatment-resistant forms. Research indicates that cannabidiol (CBD)-dominant products show particular promise for paediatric epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome.

Chronic pain conditions represent another major focus area. Studies investigating cannabis for neuropathic pain, fibromyalgia, and cancer-related pain have demonstrated variable but often positive outcomes. A 2024 meta-analysis of UK-based studies found that 58% of chronic pain patients reported meaningful pain reduction with medical cannabis use.

Multiple sclerosis-related spasticity has shown particularly robust responses to treatment. Research from 2024 indicates that 71% of MS patients receiving cannabis-based treatments experienced improvements in spasticity scores. Cancer-related symptoms, including chemotherapy-induced nausea and loss of appetite, continue to be investigated, with early 2024 data proving encouraging for symptom management.

Emerging research areas in 2024 include Post-Traumatic Stress Disorder (PTSD), anxiety disorders, and treatment-resistant depression. Whilst evidence remains preliminary, several UK research groups have received funding to conduct randomised controlled trials examining these indications.

Cannabinoid Pharmacology and Research Developments

2024 has seen significant advances in understanding cannabinoid pharmacology. Researchers at Oxford University have published groundbreaking work on the entourage effect—the theory that multiple cannabis compounds work synergistically rather than individually. Their findings suggest that full-spectrum products may offer advantages over isolates for certain conditions, though this remains an active area of investigation.

The ratio of tetrahydrocannabinol (THC) to CBD continues to be refined in clinical applications. Current research supports CBD-dominant or CBD-only products for paediatric conditions, whilst balanced THC:CBD ratios show promise for adult pain conditions. Standardisation of cannabis-based products remains a critical research focus, as variability in cannabinoid content can affect clinical outcomes.

Regulatory Framework and Access to Research

The Medicines and Healthcare Products Regulatory Agency (MHRA) continues to oversee cannabis-based medicinal products with rigorous standards. As of 2024, only four cannabis-based products have received full MHRA approval: Sativex (nabiximols), Epidiolex (cannabidiol), Marinol (dronabinol), and Cesamet (nabilone). However, specialist clinicians can prescribe unlicensed CBMPs where evidence supports their use and licensed alternatives are unavailable.

Access to medical cannabis remains limited, with approximately 13,000 patients estimated to be receiving prescriptions through NHS or private channels. This relatively small number reflects both regulatory caution and ongoing evidence-gathering phases, which are essential for expanding future access.

Patient Safety and Adverse Event Monitoring

Contemporary cannabis research in the UK emphasises rigorous safety monitoring. Comprehensive studies tracking adverse events have found that medical cannabis, when properly prescribed and monitored, demonstrates a favourable safety profile. Common side effects—such as dizziness, dry mouth, and fatigue—are typically mild and manageable.

However, research has identified important cautions: drug interactions with cytochrome P450 inhibitors, potential cognitive effects in vulnerable populations, and risks associated with use in psychosis-prone individuals. 2024 research continues refining patient selection criteria to maximise benefits whilst minimising risks.

The Future of Cannabis Research in the UK

The UK government has committed to continuing support for cannabis research, with approximately £3 million in dedicated funding allocated through various research councils for 2024-2025. This investment signals confidence in the research agenda and commitment to expanding the evidence base.

Future research priorities include larger randomised controlled trials, longer-term safety studies, investigations into optimal dosing strategies, and exploration of novel indications. The expansion of paediatric research remains particularly important, as does investigation into potential benefits for elderly patients.

Cannabis research in the UK continues to strengthen the scientific foundation for medical applications. As 2024 progresses, expect continued evidence accumulation that will likely inform future policy decisions regarding access and availability of cannabis-based treatments throughout the United Kingdom.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Medical cannabis is a prescription-only medicine in the UK. Always consult a qualified healthcare professional. CannaZen is an information platform, not a medical provider.